[{"orgOrder":0,"company":"Aerogen","sponsor":"Polarean","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"6","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Aerogen","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"9","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Epoprostenol Sodium","moa":"Prostanoid IP receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerogen \/ Ohio State University","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Ohio State University"},{"orgOrder":0,"company":"Aerogen","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"AP-002","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists||RANKL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20999999999999999,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AP-002","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aerogen \/ Undisclosed"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aerogen \/ CanSino Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aerogen \/ CanSino Biologics"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aerogen \/ CanSino Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aerogen \/ CanSino Biologics"}]

Find Clinical Drug Pipeline Developments & Deals by Aerogen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Salbutamol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Insufficiency.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 07, 2025

                          Lead Product(s) : Salbutamol Sulphate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Università degli Studi di Ferrara

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : AeroFact (SF-RI 1) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.

                          Product Name : AeroFact

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 15, 2025

                          Lead Product(s) : SF-RI 1

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Albuterol Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 21, 2024

                          Lead Product(s) : Salbutamol Sulphate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Recipient : Polarean

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Convidecia Air™ (homologous inactivated covid-19 vaccine) has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observ...

                          Product Name : Convidecia

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 14, 2022

                          Lead Product(s) : Ad5-nCoV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : CanSino Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in ...

                          Product Name : AeroFact

                          Product Type : Miscellaneous

                          Upfront Cash : $20.0 million

                          December 22, 2021

                          Lead Product(s) : AP-002

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Recipient : Nuance Pharma

                          Deal Size : $212.5 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine, Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.

                          Product Name : Convidecia

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 09, 2021

                          Lead Product(s) : Ad5-nCoV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : CanSino Biologics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system .

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          October 23, 2020

                          Lead Product(s) : SNG001

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Recipient : Synairgen

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Epoprostenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 30, 2020

                          Lead Product(s) : Epoprostenol Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Ohio State University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank